Petteri Rinne profile picture
Docent, Institute of Biomedicine


+358 29 450 4632
+358 50 560 9497
Kiinamyllynkatu 10

Areas of expertise

Cardiovascular diseases
Heart Failure
Cardiovascular Pharmacology
Experimental Research


I work currently as Academy Research Fellow at the University of Turku. I graduated from the Health Biosciences Master's degree programme (University of Turku) with a major in Drug Development. Thereafter, I conducted my PhD studies at the Department of Pharmacology, Drug Development and Therapeutics and graduated in 2013. After doing a short postdoctoral research period at the Turku PET Centre, I was awarded a 3-year postdoctoral fellowship from the Academy of Finland. During this period, I did research at the Institute for Cardiovascular Prevention (IPEK) in Munich, Germany. My current affiliation is Research Center For Integrative Physiology and Pharmacology, Institute of Biomedicine, and my office is located in Medisiina C building.  


I am actively involved in teaching activities in courses related to basic and advanced pharmacology, particularly in courses in cardiovascular pharmacology. As I am currently holding a research-oriented position, my contribution to teaching is not very extensive, but besides occasional lecturing, I am mentoring as well as supervising undergraduate and PhD students in their thesis projects.    


My current research projects focus on the role of melanocortin and  lipid signalling in cardiovascular diseases. In particular, the research aims at evaluating the therapeutic potential of targeting these systems for the management of atherosclerosis. We utilize both loss- and gain-of-function models as well as pharmacological and genetic approaches to advance our understanding of the roles of these mediators in atherosclerosis. The projects also combine various in vitro and in vivo models to achieve an extensive view of the underlying molecular-level mechanisms.
Coronary artery disease arising from atherosclerosis is a common form of cardiovascular disease and an important public health challenge worldwide. It is lacking effective treatments that would specifically target and reverse the underlying pathology and disease progression, highlighting the unmet medical need. Our research projects contribute to this need by exploring the possible therapeutic benefits of targeting melanocortin and lipid mediators in atherosclerosis.   


Sort by:

Deep Learning-Based Image Analysis of Liver Steatosis in Mouse Models (2023)

American Journal of Pathology
Mairinoja Laura, Heikelä Hanna, Blom Sami, Kumar Darshan, Knuuttila Anna, Boyd Sonja, Sjöblom Nelli, Birkman Eva-Maria, Rinne Petteri, Ruusuvuori Pekka, Strauss Leena, Poutanen Matti
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

GPR55 in B cells limits atherosclerosis development and regulates plasma cell maturation (2022)

Nature cardiovascular research
Guillamat-Prats R, Hering D, Derle A, Rami M, Härdtner C, Santovito D, Rinne P, Bindila L, Hristov M, Pagano S, Vuilleumier N, Schmid S, Janjic A, Enard W, Weber C, Maegdefessel L, Faussner A, Hilgendorf I, Steffens S
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice (2020)

JACC: Basic to Translational Science
Mia Ståhle, Johanna M.U. Silvola, Sanna Hellberg, Margreet de Vries, Paul H. A. Quax, Jeffrey Kroon, Petteri Rinne, Alwin de Jong, Heidi Liljenbäck, Nina Savisto, Anna Wickman, Erik S.G. Stroes, Seppo Ylä-Herttuala, Pekka Saukko, Tommy Abrahamsson, Knut Pettersson, Juhani Knuuti, Anne Roivainen, Antti Saraste,
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))